BioSpace News Archive

Quest Diagnostics (NYSE:DGX) and Mercy today announced that Quest has completed its previously announced acquisition of the outreach laboratory services business of Mercy in an all-cash asset transaction

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID-19 vaccine

ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June 2, 2021, beginning at 10 a.m. Eastern Time.

According to our latest study on “Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product, and Distribution Channel,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.

According to The Insight Partners market research study of “Nucleic Acid Amplification, Detection, and Diagnostics Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Nucleic Acid, Process, Product Type, Technology, Application, End User, and Geography”, the global nucleic acid amplification, detection, and diagnostics market is expected to reach US$ 38,162.68 million by 2027 from US$ 14,014.59 million in 2019.

Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced the voting results from the Company’s annual and special meeting of shareholders held today, June 1, 2021.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) for elamipretide

Predictive Health Diagnostics Company, Inc. (“PHDC” or “the Company”), a diagnostics development platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced its business strategy and development plan, including upcoming corporate milestones

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 89,800 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy